##semicolon##
болезнь Паркинсона, микробиота, дисбиоз, пробиотикотерапия.##submission.citations##
Bäckhed F., Roswall J., Peng Y., Feng Q., Jia H., Kovatcheva-Datchary P., et al. Dynamics and stabilization of the human gut microbiome during the first year of life. Cell Host Microbe. 2015;17(5):690–703. doi: 10.1016/j.chom.2015.04.004.
Bisaglia M., Mammi S., Bubacco L. Structural insights on physiological functions and pathological effects of alpha-synuclein. FASEB J. 2009; 23:329–340.
Galland L. The gut microbiome and the brain. J Med Food. 2014;17(12):1261–72. http://dx.doi.org/ 10.1089/jmf.2014.7000 PMID: 25402818.
Halliwell B. Reactive oxygen species and the central nervous system. J Neurochem. 1992;59:161992; 59:1609lberer M.M., Buchanan K.L., Klein M.E., et al. A gut-brain neural circuit for nutrient sensory transduction. Science. 2018;361(6408): eaat5236. http://dx. doi.org/10.1126/science.aat5236 PMID: 30237325.
Mulak A., Bonaz B. Brain-gut-microbiota axis in Parkinson’s disease. World J Gastroenterol. 2015;21 (37):10609–20. http://dx.doi.org/10.3748/wjg.v21.i3 7.10609 PMID: 26457021.
Nakabeppu Y., Tsuchimoto D., Yamaguchi H., Sakumi K. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res.2007; 85:9199–934.
Nasir Uddin Mahbub, Minarul Islam, Seong-Tshool Hong. Dysbiosis of the gut microbiota and its effect on α-synuclein and prion protein misfolding: consequences for neurodegeneration. Front. Cell. Infect. Microbiol. 16 February 2024; Sec. Intestinal Microbiome. Volume 14. https://doi.org/10.3389/fcimb.2024. 1348279.
Octavian C. I., Gisela G., Ioana L., Emilia M. Bacterial products initiation of alpha-synuclein pathology: an in vitro study. Scientific Reports. 2024; 14:302024; 14:30306ni C., D’Antongiovanni V., Miraglia F., et al. Enteric α-synuclein impairs intestinal epithelial barrier through caspase-1-inflammasome signaling in Parkinson’s disease before brain pathology. NPJ Parkinsons Dis. 2022;8(1):9.
Phillips R.J., Walter G.C., Wilder S.L., Baronowsky E.A., Powley T.L. Alpha-synuclein-immunopositive myenteric neurons and vagal preganglionic terminals: autonomic pathway implicated in Parkinson's disease? Neuroscience. 2008;153(3):733–50. doi: 10.1016 /j. neuroscience.2008.02.074.
Qin J., Li R., Raes J., Arumugam M., Burgdorf K.S., Manichanh C., et al. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010; 464(7285): 59–65. doi: 10.1038/nature 08 821.
Shannon K.M., Keshavarzian A., Dodiya H.B., et al. Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases. Mov Disord. 2012;27(6):716–9. doi: 10.1002/mds.25 020.
Spillantini M.G., Schmidt M.L., Lee V.M., Trojanowski J.Q., Jakes R., Goedert M. Alpha-synuclein in Lewy bodies. Nature. 1997;388(6645):839–40. https: //doi.org/10.1038/42166.
Stockdale S.R., Draper L.A., O’Donovan S.M., et al. Alpha-synuclein alters the faecal viromes of rats in a gut-initiated model of Parkinson’s disease. Commun Biol. 2021;4(1):1140.
Terada M., Suzuki G., Nonaka T., Kametani F., Tamaoka A., Hasegawa M. The effect of truncation on prion-like properties of α-synuclein. J Biol Chem. 2018;293(36):13910–20. http://dx.doi.org/10.1074/j bc.RA118.001862 PMID: 30030380.
Yang N.J., Chiu I.M. Bacterial signaling to the nervous system through toxins and metabolites. J Mol Biol. 2017;429(5):587–605. http://dx.doi.org/10.10 16/j.jmb.2016.12.023 PMID: 28065740.